Simultaneous silencing of ACSL4 and induction of GADD45B in hepatocellular carcinoma cells amplifies the synergistic therapeutic effect of aspirin and sorafenib

Sorafenib is currently the only US Food and Drug Administration (FDA)-approved molecular inhibitor for the systemic therapy of advanced hepatocellular carcinoma (HCC). Aspirin has been studied extensively as an anti-inflammation, cancer preventive and therapeutic agent. However, the potential synerg...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Cell Death Discov
Auteurs principaux: Xia, Hongping, Lee, Kee Wah, Chen, Jianxiang, Kong, Shik Nie, Sekar, Karthik, Deivasigamani, Amudha, Seshachalam, Veerabrahma Pratap, Goh, Brian Kim Poh, Ooi, London Lucien, Hui, Kam M
Format: Artigo
Langue:Inglês
Publié: Nature Publishing Group 2017
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5592242/
https://ncbi.nlm.nih.gov/pubmed/28900541
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/cddiscovery.2017.58
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires